Nephrology & Hypertension Research
BENCHMARK RESEARCH
Dr. Peter Igarashi Lab
The Igarashi laboratory focuses on transcription gene regulation, kidney development, and kidney diseases including polycystic kidney disease (PKD), and autosomal dominant tubulointerstitial kidney disease (ADTKD). The laboratory has produced unique lines of transgenic mice that have been widely utilized for studies involving kidney-specific transgene expression and gene targeting.
Current Research Projects
Hepatocyte Factor-1β regulation of axon guidance signaling in the developing kidney
HNF-1β is essential for kidney development. Using ChIP-seq, we identified novel HNF-1β binding targets during kidney development. We found that HNF-1β binds to and regulates the expression of axon guidance genes in kidney epithelial cells. We are investigating the role these genes play in directing kidney development, and how their dysregulation may lead to defects in kidney development.
The regulation of the canonical Wnt signaling by HNF-1beta
To investigate the molecular mechanisms on how HNF-1beta regulates Wnt pathway gene transcription and the significance of dysregulated Wnt signaling in renal cystogenesis and fibrogenesis using mouse models.
Role of LncRNA in pathogenesis of PKD
LncRNAs have been recently implicated in a range of diseases including cancer; however little is known about their role in kidney development or kidney disease. Dr. Aboudehen is focused on conducting work aimed at discovering therapeutic LncRNAs that prevents or mitigates cyst formation and/or progression in PKD. Utilizing multiple mouse models of PKD, a comprehensive list of known and novel LncRNAs that are dysregulated in PKD have been established and are currently being investigated.
Utilizing ex-vivo kidney culture to investigate ADPKD
The paucity of in vitro models to investigate ADPKD has hindered research towards identifying therapeutic targets and novel treatments. Recent novel findings show the feasibility of utilizing the metanephric organ culture (MOC) to rapidly and inexpensively screen and identify novel genes and pathways that are involved in cystogenesis. Utilizing adeno-associated viruses to manipulate gene expression in the organ culture demonstrated the feasibility of utilizing this approach.
CLINICAL/EPIDEMIOLOGICAL RESEARCH
Blood Pressure
Systolic Blood Pressure Intervention Trial (SPRINT)
Blood Pressure and Kidney Function - SPRINT vs Electronic Health Record Data
Principal Investigator
Paul Drawz, MD
Program Manager
Nayanjot Kaur Rai, MPH, BDS
rai00041@umn.edu
Study Coordinator
Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu
Preventing Cognitive Decline by Reducing BP Target Trial (PCOT)
Principal Investigator
Paul Drawz, MD
Program Manager
Nayanjot Kaur Rai, MPH, BDS
rai00041@umn.edu
Study Coordinator
Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu
COVID-19
More Coming Soon
Diabetes Kidney Disease
More Coming Soon
FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
Phase 3 Trial
A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
Principal Investigator
Michelle Rheault, MD
Study Coordinator
Amy Hanson, CCRC
amhanson@umn.edu
IGA NEPHROPATHY
Phase 3 Trial
A Randomized, Double-blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA (Immunoglobulin A) Nephropathy at Risk of Progressing to End-stage Renal Disease (NefIgArd)
Principal Investigator
Surabhi Thakar, MD
Co-Investigator
Katti Woerner, MD
Study Coordinators
Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu
Mary McDonald, RN, CCRP
mcdo0664@umn.edu
Phase 3 Trial
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN)
Principal Investigator
Patrick H. Nachman, MD
Study Coordinators
Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu
Mary McDonald, RN, CCRP
mcdo0664@umn.edu
HYPERTENSION
Systolic Blood Pressure Intervention Trial (SPRINT)\
Principal Investigator
Paul Drawz, MD
Study Coordinator
Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu
KIDNEY AND PANCREAS TRANSPLANTATION
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)
Principal Investigator
Samy Riad, MD, MS
Co-Investigator
Richard Spong, MD
Study Coordinator
Ghislaine Feussom
feuss001@umn.edu
Phase 3
A Randomized, Controlled, Multi-Center, Safety and Efficacy Study of FCR001 Cell-Based Therapy Relative to a Tacrolimus and Mycophenolate-Based Regimen in de Novo Living Donor Renal Transplant Recipients, and Safety in FCR001 Donors (FREEDOM-1)
Principal Investigator
Erik Finger, MD, PhD
Co-Investigator
Samy Riad, MD, MS
Study Coordinator
Dave Ankarlo
anka0004@umn.edu
Immunosuppression Reduction in Failed Allograft Guided by cfDNA
Principal Investigator
Samy Riad, MD, MS
Study Coordinator
Ghislaine Feussom
feuss001@umn.edu
Cf-DNA Assay During Treatment of Acute Rejection-Pilot Study
Principal Investigator
Arthur Matas, MD
Co-Investigators
Samy Riad, MD, MS
Study Coordinators
Marcia Brott
brott001@umn.edu
Amanda Contreras
contr014@umn.edu
Phase 1 and Phase 2 Trial
PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant
Principal Investigator
Michelle Rheault, MD
Co-Investigator
Samy Riad, MD, MS
Study Coordinators
Marcia Brott
brott001@umn.edu
Thu Danh, MPH
danhx005@umn.edu
MEMBRANOUS NEPHROPATHY
Phase 2 Trial
Efficacy of Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (REBOOT)
Principal Investigator
Patrick Nachman, MD
Study Coordinators
Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu
Mary McDonald, RN, CCRP
mcdo0664@umn.edu
NEPHROTIC SYNDROME
The Nephrotic Syndrome Study Network (NEPTUNE)
Principal Investigator
Patrick Nachman, MD
Co-Principal Investigator
Michelle Rheault, MD
Study Coordinators
Mary McDonald, RN, CCRP
mcdo0664@umn.edu
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase 2 Trial
Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects With Systemic Lupus Erythematosus
Principal Investigator
Dr. Parastoo Fazeli
Study Coordinator
Julie Scherber
sche0245@umn.edu
Phase 3 Trial
A Two-year, Phase III Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Evaluate the Safety, Efficacy, and Tolerability of 300 mg s.c. Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis
Principal Investigator
Patrick Nachman, MD
Co-Investigators
Surabhi Thakar, MD
Study Coordinator
Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu
Phase 3 Trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY)
Principal Investigator
Surabhi Thakar, MD
Study Coordinator
Mary McDonald, RN, CCRP
mcdo0664@umn.edu
StudyFinder is a University of Minnesota website that displays a searchable listing of studies, which are extracted from ClinicalTrials.gov. At StudyFinder you can explore University health studies currently seeking participants.
Clinicaltrials.gov is a database of privately and publicly funded clinical studies conducted around the world.